Endocyte, Inc.
(NASDAQ : ECYT)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Binary Options?
We'll teach you the best ways to trade binaries.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson 0.19%178.470.7%$1353.07m
MRKMerck & Co., Inc. 1.88%94.380.7%$1234.71m
PFEPfizer Inc. 1.72%52.530.9%$1114.05m
LLYEli Lilly & Co. 0.80%329.811.1%$1034.41m
BMYBristol-Myers Squibb Co. 0.96%76.691.0%$1001.04m
ABBVAbbVie, Inc. 0.30%154.391.9%$963.10m
AZNAstraZeneca Plc 1.04%66.191.0%$475.85m
SGENSeagen Inc. 0.06%176.885.7%$326.27m
GSKGSK Plc 0.09%43.340.2%$272.64m
TPTXTurning Point Therapeutics, Inc. -0.09%75.090.0%$199.12m
HZNPHorizon Therapeutics Plc -0.22%82.585.4%$173.71m
NVSNovartis AG -0.59%83.780.2%$171.24m
MRTXMirati Therapeutics, Inc. 1.54%73.071.6%$153.14m
ALNYAlnylam Pharmaceuticals, Inc. 0.32%151.218.1%$150.79m
NVONovo Nordisk A/S -0.91%110.230.1%$147.02m

Company Profile

Endocyte, Inc., a biopharmaceutical company, develops receptor-targeted therapeutics to treat cancer and autoimmune/inflammatory diseases. The company provides EC17, a folate-targeted hapten therapy drug to treat metastatic renal and ovarian cancer; EC145, a folate-targeted chemotherapeutic conjugate to treat various tumors, including cancers of the breast, lung, and blood; EC0225, a targeted chemotherapy drug; BMS753493, a folate-targeted anti-cancer therapy drug; EC0434 to target folate receptor positive tumors; and EC0305, an anti-cancer therapy drug. It also offers EC0286, a folate-targeted small molecule for the treatment of inflammatory diseases; and EC20, a folate-targeted radiopharmaceutical imaging agent to identify folate-receptor positive cancers. The company was founded in 1996 and is based in West Lafayette, Indiana.